Reliance Life Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RELIANCE LIFE, and what generic and branded alternatives to RELIANCE LIFE drugs are available?
RELIANCE LIFE has three approved drugs.
Summary for Reliance Life
| US Patents: | 0 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Reliance Life
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reliance Life | CAPECITABINE | capecitabine | TABLET;ORAL | 211724-002 | Apr 27, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Reliance Life | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 211899-002 | May 25, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Reliance Life | CAPECITABINE | capecitabine | TABLET;ORAL | 211724-001 | Apr 27, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Reliance Life | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 211899-001 | May 25, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Reliance Life Sci | BORTEZOMIB | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 211898-001 | Oct 11, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
